VERAXA Biotech accelerates transition to clinical-stage development company with Synimmune acquisition
The addition of a clinical-stage FLT3-targeting cancer antibody program acts as steppingstone for further pipeline and technology expansion.
Torsten Buergermeister Joins VERAXA Biotech GmbH as Chief Financial Officer
The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.
VERAXA Biotech GmbH Appoints Dr. Lars Hufnagel to Chief Technical Officer
Lars Hufnagel will be responsible for advancing VERAXA’s antibody screening and ADC technologies by further developing its droplet-based microfluidic screening technology.